These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 15232170)
1. Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF Indian J Med Res; 2004 May; 119 Suppl():88-94. PubMed ID: 15232170 [TBL] [Abstract][Full Text] [Related]
2. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479 [TBL] [Abstract][Full Text] [Related]
3. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615 [TBL] [Abstract][Full Text] [Related]
4. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107 [TBL] [Abstract][Full Text] [Related]
5. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510 [TBL] [Abstract][Full Text] [Related]
6. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Olive C; Batzloff MR; Horváth A; Wong A; Clair T; Yarwood P; Toth I; Good MF Infect Immun; 2002 May; 70(5):2734-8. PubMed ID: 11953422 [TBL] [Abstract][Full Text] [Related]
7. Method for the synthesis of highly pure vaccines using the lipid core peptide system. Moyle PM; Olive C; Good MF; Toth I J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293 [TBL] [Abstract][Full Text] [Related]
8. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Hayman WA; Toth I; Flinn N; Scanlon M; Good MF Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119 [TBL] [Abstract][Full Text] [Related]
9. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Skwarczynski M; Toth I Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338 [TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Batzloff M; Yan H; Davies M; Hartas J; Good M Indian J Med Res; 2004 May; 119 Suppl():104-7. PubMed ID: 15232173 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Fujita Y; Abdel-Aal AB; Wimmer N; Batzloff MR; Good MF; Toth I Bioorg Med Chem; 2008 Oct; 16(19):8907-13. PubMed ID: 18789866 [TBL] [Abstract][Full Text] [Related]
13. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage. Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249 [TBL] [Abstract][Full Text] [Related]
14. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. Moyle PM; Olive C; Ho MF; Good MF; Toth I J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142 [TBL] [Abstract][Full Text] [Related]
16. Prospecting for new group A streptococcal vaccine candidates. McMillan DJ; Davies MR; Browning CL; Good MF; Sriprakash KS Indian J Med Res; 2004 May; 119 Suppl():121-5. PubMed ID: 15232176 [TBL] [Abstract][Full Text] [Related]
17. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant. Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764 [TBL] [Abstract][Full Text] [Related]
18. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857 [TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610 [TBL] [Abstract][Full Text] [Related]
20. Mapping a conserved conformational epitope from the M protein of group A streptococci. Relf WA; Cooper J; Brandt ER; Hayman WA; Anders RF; Pruksakorn S; Currie B; Saul A; Good MF Pept Res; 1996; 9(1):12-20. PubMed ID: 8727479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]